Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study reported that in rat retinas under high pressure, allopregnanolone synthesis increased and helped reduce pressure-induced damage through GABAA receptors, suggesting potential therapeutic use in glaucoma.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.

This study found that using hair steroid profiling, dutasteride treatment led to reduced dihydrotestosterone levels and DHT/testosterone ratio in patients with male-pattern baldness.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

Stopping sunscreen use on the forehead led to hair regrowth in a woman with frontal fibrosing alopecia.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

This review examines hormonal therapies, including finasteride, dutasteride, spironolactone, and oral contraceptives, for treating hidradenitis suppurativa, summarizing various clinical study outcomes but reporting no new clinical results.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

This study found that dutasteride completely suppressed the formation of 5alpha-dihydro metabolites in cultured human skin cells, suggesting its potential use in acne and androgenetic alopecia.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.